Dapagliflozin ameliorates arterial stiffness, endothelial glycocaclyx and myocardial performance in non-diabetic STEMI patients: a 3-month follow-up study
Sodium glucose Cotransporter-2 inhibitor (SGLT2i) have been recently administered efficiently in the acute phase of Acute Myocardial Infarctions (AMI) in patients without diabetes or heart failure. We aimed to address the effects of dapagliflozin in arterial wall elastic properties, thickness of endothelia...